The Study
Dose–response relationship between statin therapy and glycaemia in community‐based patients with type 2 diabetes: the Fremantle Diabetes Study
This study looked at people with diabetes who took different doses of statins and noticed that those on higher doses tended to have higher blood sugar over time. But it didn’t randomly assign people to different doses, so we can’t be sure the statins caused the rise — maybe other things changed too.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
This study looked at people with type 2 diabetes who started taking statins and checked if their blood sugar got worse over time.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 541 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1A 1% rise in HbA1c is clinically meaningful—it’s like going from a well-controlled to a poorly controlled diabetes level.
- 2Low-dose statins: no change in blood sugar.
- 3Medium-dose: blood sugar went up by 0.22%.
- 4High-dose: blood sugar went up by 1.05%.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes
Year
2016
Authors
Timothy M. E. Davis, Imran Badshah, S. A. Chubb, W. Davis
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.